<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01814163</url>
  </required_header>
  <id_info>
    <org_study_id>GECP 09-02</org_study_id>
    <nct_id>NCT01814163</nct_id>
  </id_info>
  <brief_title>Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab</brief_title>
  <acronym>ANGIOMET</acronym>
  <official_title>Observational Studies to Explore the Relation Between Angiogenic Markers and the Treatment Response With Carboplatin, Paclitaxel and Bevacizumab in First Line of Advanced Non-small-cell Lung Cancer With Non- Squamous Histology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Lung Cancer Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pharmacogenomic study with carboplatin, paclitaxel and bevacizumab as first line
      therapy in patients with non-squamous advanced non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a observational study prospectively followed post-authorization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between angiogenesis markers and progression free survival.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overal survival</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival at 12 and 24 months</measure>
    <time_frame>12-24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment security</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Nonsquamous Nonsmall Cell Neoplasm of Lung</condition>
  <arm_group>
    <arm_group_label>Paclitaxel, carboplatin and bevacizumab</arm_group_label>
    <description>Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel, carboplatin and bevacizumab</intervention_name>
    <description>Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression</description>
    <arm_group_label>Paclitaxel, carboplatin and bevacizumab</arm_group_label>
    <other_name>Taxol, carboplatin, avastin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-small cell lung cancer advanced unresectable, metastatic or recurrent,
        non-squamous and untreated with chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients should sign inform consent before inclusion in the study that specifies that
             the clinical treatment entails consent for the analysis of biological samples of tumor
             and blood.

          2. Histologically confirmed diagnosis of advanced non small-cell lung carcinoma,
             non-squamous cell

          3. Patients age 18 years or more

          4. Patients will be candidates to received a first line of chemotherapy of carboplatin,
             paclitaxel and bevacizumab as the best therapeutic option.

          5. Evidence of measurable disease per Response Evalutation Criteria in Solid tumors
             (RECIST)

          6. Patients must be avalaible for clinical follow-up

          7. Patients with the following hematologic/biochemical values:

               -  Absolute Neutrophil Count ANC &gt; 1500/µl.

               -  Platelets &gt; 100.000 /µl.

               -  Hemoglobine &gt; 10 g/dl.

               -  Bilirrubin &lt; 1.5 mg/dl.

               -  Aspartate aminotransfereasa (AST) and Alanine transaminase (ALT) ≤ 3 x LSN,
                  except in case of hepatic metastases: upper 5 x LSN

               -  Creatinine clearance ≥ 45 ml/min.

        Exclusion Criteria:

          1. Previous treatment for advanced disease. Chemotherapy is allowed if the initial
             diagnosis of the patient is limited disease and the patient has received adjuvant or
             neadjuvant treatment

          2. history of haemoptysis (defined as at least half a teaspoon's emission of red blood)
             in the 3 months prior to inclusion

          3. evidence by CT of tumor cavitations, or tumours invading or abutting major blood
             vessels

          4. Known or suspected brain metastases non-treated.

          5. Major surgery within 28 days of starting treatment.

          6. Minor surgery within 24 hours before starting the treatment.

          7. Non-controlled hypertension (systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg).

          8. Patients with coronary disease or uncontrolled arrhytmia, uncontrolled cerebrovascular
             disease and other clinical conditions that, in judgment of the investigator,
             contraindicate the patient's participation in the study.

          9. History or evidence of bleeding diathesis or hereditary coagulopathy.

         10. Contraindication or suspected allergy to the products under investigation in the
             study:: paclitaxel, carboplatine or bevacizumab.

         11. Patients who are pregnant or breasfeeding. Women of childbearing potencial must have a
             negative pregnancy test performed within 7 days before the onset of treatment.

         12. Substance abuse of clinical, psychological or social conditions that can undermine the
             validity of the informed consent or protocol compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bartomeu Massutí, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Gen. Univ.Alicante</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Camps, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Gen. Univ. Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier de Castro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Gen. Universitario Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castellón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Elche</name>
      <address>
        <city>Elche (Alicante)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de L'Hospitalet</name>
      <address>
        <city>l'Hospitalet (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Insular Gran Canaria</name>
      <address>
        <city>Las Palmas</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Quirón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Rotger</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ntra Sra Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Gen. Univ. Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gecp.org/</url>
    <description>Spanish Lung Cancer Group website</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>March 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>March 18, 2013</last_update_submitted>
  <last_update_submitted_qc>March 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First line treatment</keyword>
  <keyword>Non small cell lung cancer, non squamous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

